<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351427</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1223</org_study_id>
    <nct_id>NCT02351427</nct_id>
  </id_info>
  <brief_title>Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation</brief_title>
  <official_title>Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bortezomib is effective in the treatment of
      acute cellular rejection after kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When acute cellular rejection occurred in kidney allograft, investigators administer high
      dose steroid. However, there is insufficient effect in about 20-30%. Bortezomib acts not only
      on plasma cells, but also T cells, B cells and dendritic cells. In addition, bortezomib is
      relatively safe drug compared to thymoglobulin which investigators use in the cases of
      steroid failure. Therefore, investigators administer bortezomib with steroid in one group,
      and compared the group with the other group in which conventional steroid treatment is done.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Day 14</time_frame>
    <description>Investigators measure patients' serum creatinine at day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of steroid failure</measure>
    <time_frame>Day 7</time_frame>
    <description>Steroid failure is defined as serum creatinine at day 8 ≥ serum creatinine at day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Month 1</time_frame>
    <description>Investigators measure patients' serum creatinine at month 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>Until 1 year after intervention</time_frame>
    <description>Infection as measured by clinical, laboratory and microbiological data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of Rejection</measure>
    <time_frame>Until 1 year after intervention</time_frame>
    <description>Recurrence of rejection as measured by clinical and laboratory data with graft biopsy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7
with
Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.</description>
    <arm_group_label>Bortezomib</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid</intervention_name>
    <description>Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.</description>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  living donor kidney transplantation recipients

          -  patients who were performed kidney biopsies because of laboratory and clinically
             suspected rejection

          -  Biopsy proven acute cellular rejection (Banff I - IIA) with C4d negative

          -  Single luminex panel reactive antibody (PRA) I &amp; II mean fluorescent intensity (MFI) &lt;
             3000

        Exclusion Criteria:

          -  patients who received other major organ transplantation

          -  combined with urinary tract infection or obstruction

          -  combined with acute antibody mediated rejection

          -  poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su-Kil Park, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Su-Kil Park, M.D., PhD</last_name>
    <phone>82-2-3010-3263</phone>
    <email>skpark@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chung Hee Baek, M.D.</last_name>
    <phone>82-2-3010-1481</phone>
    <email>bch393@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su-Kil Park, M.D., PhD</last_name>
      <phone>82-2-3010-3263</phone>
      <email>skpark@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Chung Hee Baek, M.D.</last_name>
      <phone>82-2-3010-1481</phone>
      <email>bch393@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lemy A, Toungouz M, Abramowicz D. Bortezomib: a new player in pre- and post-transplant desensitization? Nephrol Dial Transplant. 2010 Nov;25(11):3480-9. doi: 10.1093/ndt/gfq502. Epub 2010 Sep 8. Review.</citation>
    <PMID>20826741</PMID>
  </reference>
  <reference>
    <citation>Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int. 2012 Jun;81(11):1067-74. doi: 10.1038/ki.2011.502. Epub 2012 Feb 15. Review.</citation>
    <PMID>22336990</PMID>
  </reference>
  <reference>
    <citation>Tzvetanov I, Spaggiari M, Joseph J, Jeon H, Thielke J, Oberholzer J, Benedetti E. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature. Transplant Proc. 2012 Dec;44(10):2971-5. doi: 10.1016/j.transproceed.2012.02.037. Review.</citation>
    <PMID>23195008</PMID>
  </reference>
  <reference>
    <citation>Schmidt N, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, Hanseman DJ, Woodle ES. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation. 2012 Aug 27;94(4):352-61.</citation>
    <PMID>22836132</PMID>
  </reference>
  <reference>
    <citation>Hu X, Xu J, Sun A, Shen Y, He G, Guo F. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity. Leuk Lymphoma. 2011 Dec;52(12):2393-5. doi: 10.3109/10428194.2011.593271. Epub 2011 Jul 12.</citation>
    <PMID>21745166</PMID>
  </reference>
  <reference>
    <citation>Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4.</citation>
    <PMID>22770877</PMID>
  </reference>
  <reference>
    <citation>Zain JM, O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol. 2010 Jul;92(1):33-44. doi: 10.1007/s12185-010-0614-9. Epub 2010 Jun 10. Review.</citation>
    <PMID>20535594</PMID>
  </reference>
  <reference>
    <citation>Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012 Dec;97(12):1925-8. doi: 10.3324/haematol.2012.067793. Epub 2012 Jun 11.</citation>
    <PMID>22689676</PMID>
  </reference>
  <results_reference>
    <citation>Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008 Dec 27;86(12):1754-61. doi: 10.1097/TP.0b013e318190af83.</citation>
    <PMID>19104417</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Su-Kil Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

